AFJK · Aimei Health Technology Co., Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | - | $130.2K | $41.6K | $413.4K | - | $200.0K | $309.1K | $153.6K | - | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | ($200.0K) | ($41.6K) | ($153.6K) | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - | - |
| Net Income | - | $352.0K | $425.0K | $184.7K | - | $743.5K | $609.1K | $755.5K | - | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.9K | $3.0K | $2.1K | $7.3K | $28.2K | $103.6K | $157.5K | $413.7K | $580.7K | $25.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $2.9K | $24.9K | $44.6K | $8.0K | $30.4K | $123.9K | $204.3K | $480.7K | $580.7K | - |
| Total Assets | $12.10M | $45.47M | $44.56M | $43.60M | $73.81M | $72.78M | $71.92M | $71.28M | $70.47M | - |
| Current Liabilities | $3.37M | $2.77M | $2.21M | $1.69M | $817.0K | $230.8K | $111.2K | $78.5K | $24.8K | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.06M | $3.46M | $2.90M | $2.38M | $1.51M | $920.8K | $801.2K | $768.5K | $714.8K | - |
| Stockholders' Equity | ($4.06M) | ($3.44M) | ($2.86M) | ($2.37M) | ($1.48M) | ($796.9K) | ($596.9K) | ($287.8K) | ($134.1K) | - |
| Retained Earnings | ($4.06M) | ($3.44M) | ($2.86M) | ($2.37M) | ($1.48M) | ($797.1K) | ($597.1K) | ($288.0K) | ($134.3K) | - |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($224.0K) | - | - | - | ($167.0K) | - | - |
| Investing Cash Flow | - | - | - | $30.79M | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | ($30.58M) | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | 0.0% | 0.0% | 0.0% | - | 0.0% | 0.0% | 0.0% | - | - |
| Return on assets | - | 0.8% | 1.0% | 0.4% | - | 1.0% | 0.8% | 1.1% | - | - |
| Return on equity | - | -10.2% | -14.9% | -7.8% | - | -93.3% | -102.0% | -262.5% | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.00 | 0.01 | 0.02 | 0.00 | 0.04 | 0.54 | 1.84 | 6.13 | 23.38 | - |
| Quick ratio | 0.00 | 0.01 | 0.02 | 0.00 | 0.04 | 0.54 | 1.84 | 6.13 | 23.38 | - |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.45 | 1.42 | 5.27 | 23.38 | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -2.98 | -13.22 | -15.58 | -18.42 | -49.99 | -91.34 | -120.50 | -247.71 | -525.41 | - |
| Liabilities / Assets | 0.34 | 0.08 | 0.07 | 0.05 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | -52.7% | -30.2% | -75.6% | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -174.9% | -331.6% | -379.1% | -722.8% | -1000.9% | - | - | - | - | - |
Peer comparison
Same SIC group: Blank Checks
Comparing Aimei Health Technology Co. against the 5 most active filers in the same SIC group.